VivoSeq
Other

NSCLC

12

Pipeline Programs↗

26

Active Trials↗

29

Companies Involved↗

NSCLC is an emerging landscape with 12 programs across 29 companies. The most active players are Jiangsu Hansoh Pharmaceutical Co., Ltd., CSPC Megalith Biopharmaceutical Co.,Ltd., Pfizer. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

32/100

Mech. Concentration

33/100

Completion Rate

66/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.

1 program

Phase 1C

CSPC Megalith Biopharmaceutical Co.,Ltd.

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 2S

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

78

clinical trials

Completed25 · 32%
Recruiting13 · 17%
Unknown status11 · 14%
Terminated8 · 10%
Active, not recruiting7 · 9%
Not yet recruiting6 · 8%
Other8 · 10%

Clinical Trials

Trial Activity

78 trials

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
Recruiting·OORIC Pharmaceuticals·Phase 1·NCT06816992·76 enrolled
An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC
Recruiting·—·Phase 1·NCT06083870·35 enrolled
IMPT Dose Escalation for NSCLC (HyDose)
Recruiting·UUniversity Medical Center Groningen·N/A·NCT06484491·87 enrolled
A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients
Recruiting·TTherapex Co., Ltd·Phase 1/2·NCT06186076·115 enrolled
Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
Recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 1/2·NCT05777278·29 enrolled
Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
Recruiting·PPeking University Cancer Hospital & Institute·N/A·NCT06924710·286 enrolled
Immuno-effect of Tα1 for Stage I NSCLC
Recruiting·—·N/A·NCT06598839·40 enrolled
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Recruiting·UUniversity of Kansas Medical Center·Phase 1/2·NCT04467723·25 enrolled
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1/2·NCT06754930·400 enrolled
Alectinib Pharmacokinetic in Patients With NSCLC
Recruiting·IInstituto Nacional de Cancerologia de Mexico·Phase 1/2·NCT05713006·45 enrolled
A Multicenter, Single-Arm, Phase II (Simon Two-Stage) Study of Sacituzumab Tirumotecan (SKB264) Plus Glecirasib (KRAS G12C Inhibitor) as First-Line Treatment for KRAS G12C-Mutated Advanced NSCLC
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07670013·43 enrolled
A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies
Recruiting·EEllipses Pharma·Preclinical·NCT05443126·265 enrolled
An Exploratory Study of RGL-270 in Combination With PD-1/PD-L1 Inhibitors in Patients With Unresectable Locally Advanced or Recurrent/Metastatic Non-Small Cell Lung Cancer
Recruiting·GGuangdong Association of Clinical Trials·Preclinical·NCT07652125·40 enrolled
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Active, not recruiting·Novartis logoNovartis·Phase 1·NCT03333343·105 enrolled
Phase 3 Clinical Study of AK112 for NSCLC Patients
Active, not recruiting·AAkeso·Phase 3·NCT05184712·322 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)